3-Isobutyl-cyclopentanon | 53002-97-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-Isobutyl-cyclopentanon
• 英文别名: 3-Isobutylcyclopentanone；3-(2-methylpropyl)cyclopentan-1-one
• CAS: 53002-97-4
• 化学式: C₉H₁₆O
• mdl: MFCD20361790
• 分子量: 140.225
• InChiKey: HVLJAVCVDGMFKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-Isobutyl-cyclopentanon 、 氰化钠 生成 3-Isobutyl-1-cyclopenten-1-carbonitril
  参考文献：
  名称：

  Photochemical reactions of 3-substituted cyclopentenyl ketones

  摘要：

  DOI：

  10.1021/ja00817a043
• 作为产物：
  描述：

  2-环戊烯酮 、 ISOBUTYLMAGNESIUM BROMIDE 生成 3-Isobutyl-cyclopentanon
  参考文献：
  名称：

  Photochemical reactions of 3-substituted cyclopentenyl ketones

  摘要：

  DOI：

  10.1021/ja00817a043

文献信息

• NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES
  申请人：Merck Patent GmbH

  公开号：US20160168090A1

  公开（公告）日：2016-06-16

  The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

  本发明涉及吲哚化合物及其药用可接受的组合物，用作P2X7拮抗剂，用于治疗与P2X7相关的疾病。
• PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS
  申请人：Incyte Corporation

  公开号：US20170190689A1

  公开（公告）日：2017-07-06

  The present disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that modulate the activity of phosphoinositide 3-kinases-gamma (PI3Kγ) and are useful in the treatment of diseases related to the activity of PI3Kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

  本公开提供了化合物I的化合物，或其药用盐，其调节磷脂酰肌醇3-激酶-γ（PI3Kγ）的活性，并且在治疗与PI3Kγ活性相关的疾病方面具有用途，例如自身免疫疾病、癌症、心血管疾病和神经退行性疾病。
• REDOX DRUG DERIVATIVES
  申请人：Lindsay Derek

  公开号：US20120077974A1

  公开（公告）日：2012-03-29

  The present invention provides redox drug derivatives. In particular, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, (3R,4R,5S)-4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester, (3S)-3-(aminomethyl)-5-methylhexanoic acid, (3S)-1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-α-α-diphenyl-3-pyrrolidineacetamide, (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4-(diaminomethylideneamino)-2-hydroxy-cyclopentane-1-carboxylic acid and (2R,3R,4S)-4-[(diaminomethylidene)amino]-3-acetamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid redox derivatives.

  本发明提供了氧化还原药物衍生物。特别是9-氟-2,3-二氢-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶[1,2,3-de]-1,4-苯并噁嗪-6-羧酸，1-乙基-6-氟-1,4-二氢-7-(4-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸，(3R,4R,5S)-4-(乙酰氨基)-5-氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸乙酯，(3S)-3-(氨甲基)-5-甲基己酸，(3S)-1-[2-(2,3-二氢-5-苯并呋喃基)乙基]-α-α-二苯基-3-吡咯烷乙酰胺，(1S,2S,3S,4R)-3-[(1S)-1-乙酰氨基-2-乙基-丁基]-4-(二氨基甲基亚氨基)-2-羟基-环戊烷-1-羧酸和(2R,3R,4S)-4-[(二氨基甲基亚氨基)氨基]-3-乙酰氨基-2-[(1R,2R)-1,2,3-三羟基丙基]-3,4-二氢-2H-吡喃-6-羧酸氧化还原衍生物。
• NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS
  申请人：VERNIER JEAN-MICHEL

  公开号：US20090170885A1

  公开（公告）日：2009-07-02

  This invention provided compounds of formula I where W and Z are, independently, CH or N, and where other substituents are defined herein. Such compounds are potassium channel modulators. The invention also provides a composition comprising a pharmaceutically acceptable carrier or excipient and at least one of the following: a pharmaceutically effective amount of a compound of formula I; a pharmaceutically acceptable salt of a compound of formula I; a pharmaceutically acceptable ester of a compound of formula I. The invention also provides a method of preventing or treating a disease or disorder which is affected by activities of potassium channels, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I or a salt or ester or solvate thereof.

  该发明提供了化合物I的公式，其中W和Z独立地为CH或N，其他取代基在此定义。这些化合物是钾通道调节剂。该发明还提供了一种组合物，包括药学上可接受的载体或赋形剂，以及以下至少一种：化合物I的药学有效量；化合物I的药学上可接受的盐；化合物I的药学上可接受的酯。该发明还提供了一种预防或治疗受钾通道活性影响的疾病或疾病的方法，包括向需要治疗的患者施用化合物I或其盐或酯或溶剂的治疗有效量。
• Process for preparing naphthyridine derivatives.
  申请人：Valeant Pharmaceuticals International, Inc.

  公开号：EP2311836A1

  公开（公告）日：2011-04-20

  The present invention is directed to a method of preparing a compound of formula I the method comprising the palladium-catalyzed cross-coupling of compound II with compound III:

  本发明涉及一种制备式 I 化合物的方法 该方法包括化合物 II 与化合物 III 的钯催化交叉偶联：